HOME >> BIOLOGY >> NEWS
Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting

Snowmass, Co. (September 9, 2004) Inflammatory Bowel Diseases, comprised of Crohn's Disease and ulcerative colitis, are for the most part incurable and their causes are still unknown. About 1 million Americans suffer from IBD and research around the world on new therapeutic strategies against IBD is being reported at a conference sponsored by the American Physiological Society.

Below are reports on three presentations.

  • Anti-adhesion therapy in the treatment of IBD Julian Panes and Josep M. Pique of the Gastroenterology Department of the Hospital Clinic Barcelona, Spain, note that the localization for leukocytes to inflammatory areas has key implications in the pathogenesis, diagnosis and treatment of IBD. A major effort has been directed toward identifying and characterizing the adhesion glycoproteins that enable leukocytes to bind to vascular endothelial cells. Drugs that specifically target adhesion molecules involved in leukocyte recruitment are effective in treating intestinal inflammation.

    They said that experimental models have shown that blockade of VLA-4, VCAM-1 and P-selectin afford significant amelioration of intestinal inflammation. In experimental models, response to adhesion molecule blockage varies according to the type of inflammatory intestinal condition. In humans VLA-4 immunoneutralization has been effective in inducing remission in Crohn's Disease, but no data is available for ulcerative colitis.

    The researchers call for experimental and clinical controlled trials comparing the effectiveness of different strategies of CAM blockade, and suggest that this therapeutic approach be compared with current therapies.

  • Platelet recruitment in intestinal inflammation modulated by ICAM-1, P-selectin, PSGL-1

    Researchers from LSU and the University of Muenster studied the mechanisms responsible for platelet-WBC and platelet-endothelial cell (EC) interactions that occur in exper
    '"/>



    • Contact: Mayer Resnick
    mresnick@the-aps.org
    301-634-7209
    American Physiological Society
    9-Sep-2004


    Page: 1 2 3

    Related biology news :

    1. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
    2. Novel approaches to current cellular therapies continue progress toward disease prevention
    3. Novel therapies show promise against myeloid leukemia
    4. Novel sensors help clear the air
    5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
    6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
    7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
    8. Novel bacterium detoxifies chlorinated pollutants
    9. Novel flu vaccine shows promise in mice
    10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
    11. Novel method identifies hidden genes

    Post Your Comments:
    (Date:5/21/2013)... that the nation,s land and water resources could likely ... to 25 billion gallons of algae-based fuel a year ... needs. , The findings come from an in-depth look ... grow significant amounts of algae in large, specially built ... 7 issue of Environmental Science and Technology , ...
    (Date:5/21/2013)... USC have found that a class of pharmaceuticals can ... , The drugs, known as "TSPO ligands," are currently ... at the effects of TSPO ligand in young adult ... in aged mice when pathology was quite severe," said ... of Gerontology. "TSPO ligand reduced measures of pathology and ...
    (Date:5/21/2013)... COLUMBIA, Mo. Cancers of all types become most ... body. Once cancer has reached this stage, it becomes ... numerous tumors that can develop. Now, researchers at the ... radioactive nanoparticles that target lymphoma tumor cells wherever they ... professor of oncology in the MU College of Veterinary ...
    Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
    (Date:5/21/2013)... Bellingham, WA (PRWEB) May 21, 2013 ... teacher trainings, and funds for lab equipment, 25 organizations ... relevance and importance of optics and photonics in daily ... Grants . , The organizations, located in 10 countries, ... grants to be awarded by SPIE, the international ...
    (Date:5/21/2013)... 21, 2013 Alpha Source, Inc., ... will be exhibiting for the 13th consecutive year ... Instrumentation (AAMI) 2013 Conference and Expo. The conference ... and manufacture healthcare technologies. This year’s event will ... California. , The three-day event draws over ...
    (Date:5/21/2013)... NJ (PRWEB) May 21, 2013 Savoury ... industry, has appointed Dale Braddy to Southeastern USA Sales ... bolster its sales muscle in the Southeast. ... food ingredient brokerage and supplier to food processors and ... 13 years in the food industry and has over ...
    (Date:5/21/2013)... Austin, TX (PRWEB) May 21, 2013 ... and outdoor security solutions, today announced that Genzyme, a ... more units of Door Detective® CL for a multi-use ... already installed in four other Genzyme buildings, this latest ... had with the tailgate detection device improving ...
    Breaking Biology Technology:Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3
    Cached News: